Research view
Switch to patient viewGastric and oesophageal cancer: trials that stopped early
Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.
Terminated
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Reason given in the registry “After the completion of phase IA, for business reasons it was decided to terminate the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2024.
- Ended
- Feb 2024
- Phase
- Phase 1/2
- Run by
- BioInvent International AB
- Registry record
- NCT05555251
Terminated
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Reason given in the registry “for business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.
- Ended
- Feb 2024
- Phase
- Phase 1/2
- Run by
- Celularity Incorporated
- Registry record
- NCT05207722
Withdrawn
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Reason given in the registry “Abandoned prior to launch.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Nov 2024.
- Run by
- Travera Inc
- Registry record
- NCT04985357
Terminated
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Reason given in the registry “Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2024.
- Ended
- Nov 2023
- Phase
- Phase 2
- Run by
- Hoffmann-La Roche
- Registry record
- NCT04933227
Terminated
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Reason given in the registry “slow recruitment forcing early suspension of screening and enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2024.
- Ended
- Nov 2023
- Phase
- Phase 2
- Run by
- Huazhong University of Science and Technology
- Registry record
- NCT04294784
Terminated
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Reason given in the registry “Sponsor Termination”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Nov 2024.
- Ended
- Oct 2024
- Phase
- Phase 1
- Run by
- Molecular Templates, Inc.
- Registry record
- NCT06034860
Suspended
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
Reason given in the registry “Due to a business decision resulting in the deprioritization of this project and with no safety concerns present, we (the trial sponsor) have decided to request the discontinuation of study IMM2902-101.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2024.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Registry record
- NCT05076591
Terminated
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Reason given in the registry “Program terminated due to lack of meaningful efficacy signal.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2024.
- Ended
- Oct 2024
- Phase
- Phase 1
- Run by
- Inhibrx Biosciences, Inc
- Registry record
- NCT03809624
Terminated
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
Reason given in the registry “A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2024.
- Ended
- Aug 2024
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT05780736
Terminated
Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor
Reason given in the registry “Not enough cases enrolled in the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Sept 2024
- Run by
- Peking University
- Registry record
- NCT02969122
Terminated
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Reason given in the registry “Study was terminated due to difficulty recruiting subjects and lack of efficacy”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Sept 2024.
- Ended
- Dec 2023
- Phase
- Phase 2
- Run by
- Adaptimmune
- Registry record
- NCT04752358
Terminated
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
Reason given in the registry “Business Reason”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2024.
- Ended
- May 2024
- Phase
- Phase 2
- Run by
- LianBio LLC
- Registry record
- NCT06206278
Terminated
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Reason given in the registry “PI left institution”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Johns Hopkins University
- Registry record
- NCT04583488
Withdrawn
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Reason given in the registry “No enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2024.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT05898828
Terminated
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Reason given in the registry “Futility”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jul 2024.
- Ended
- May 2024
- Run by
- Washington University School of Medicine
- Registry record
- NCT04072393
Withdrawn
Monopolar and Bipolar in Esophageal ESD
Reason given in the registry “Study being withdrawn as it is re-written now as a prospective study. Please reference new study”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2024.
- Ended
- Jun 2024
- Run by
- Baylor College of Medicine
- Registry record
- NCT05736705
Withdrawn
GI Organ Tracking Via Balloon Applicators
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.
- Ended
- May 2025
- Run by
- Washington University School of Medicine
- Registry record
- NCT05471401
Terminated
Drainless Robot-assisted Minimally Invasive Esophagectomy
Reason given in the registry “Following a safety analysis and assessment of the complications encountered by external experts, it was decided to terminate recruitment prematurely”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.
- Ended
- May 2024
- Run by
- Technische Universität Dresden
- Registry record
- NCT05553795
Terminated
The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
Reason given in the registry “recruiting issues”
Quoted unchanged from ClinicalTrials.gov; record updated 2 May 2024.
- Ended
- Dec 2023
- Phase
- Phase 4
- Run by
- Copenhagen University Hospital, Rigshospitalet
- Registry record
- NCT05354856
Terminated
Early Detection of Esophageal Cancer
Reason given in the registry “Administratively closed by the IRBO”
Quoted unchanged from ClinicalTrials.gov; record updated 1 May 2024.
- Ended
- Apr 2024
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT00341523
Withdrawn
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Reason given in the registry “The project is terminated”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Apr 2024.
- Ended
- Dec 2025
- Phase
- Early phase 1
- Run by
- Beijing Kejing Biotechnology Co., Ltd.
- Registry record
- NCT06284226
Suspended
DNX-2440 for Resectable Colorectal Liver Metastasis
Reason given in the registry “DNAtrix management decision not based on study design, safety, or site performance.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2024.
- Phase
- Phase 1
- Run by
- DNAtrix, Inc.
- Registry record
- NCT04714983
Terminated
Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
Reason given in the registry “Recruitment lower than expected and negative results.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2024.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Laval University
- Registry record
- NCT05687617
Suspended
Submucosal Tumor Removal by Endoscopic Excision Therapy
Reason given in the registry “interim analysis”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Mar 2024.
- Ended
- Feb 2025
- Run by
- Universitätsklinikum Hamburg-Eppendorf
- Registry record
- NCT04913077
Suspended
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
Reason given in the registry “difficult in enrolling participants”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2024.
- Phase
- Phase 1/2
- Run by
- Shanghai Minimally Invasive Surgery Center
- Registry record
- NCT05101616
Withdrawn
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
Reason given in the registry “Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Feb 2024.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- Erasmus Medical Center
- Registry record
- NCT05703555
Suspended
Upper GI Serial Tumour Biopsies
Reason given in the registry “To explore alternative funding streams”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2024.
- Run by
- The Christie NHS Foundation Trust
- Registry record
- NCT05233007
Terminated
Prehabilitation in Esophageal Surgery (PRESS)
Reason given in the registry “The study was terminated prematurely due to slow recruitment.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2024.
- Ended
- Jan 2024
- Run by
- Università Vita-Salute San Raffaele
- Registry record
- NCT03798951
Terminated
LITT and Pembrolizumab in Recurrent Brain Metastasis
Reason given in the registry “Sponsor terminated”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Dec 2023.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- University of Florida
- Registry record
- NCT04187872
Terminated
Systems Biology of Gastrointestinal and Related Diseases
Reason given in the registry “Lack of enrollment.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2023.
- Ended
- Nov 2023
- Run by
- Viome
- Registry record
- NCT05579444
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.